Analyst Price Target Update on Eagle Pharmaceuticals (NASDAQ:EGRX)

Eagle Pharmaceuticals (NASDAQ:EGRX): The mean estimate for the short term price target for Eagle Pharmaceuticals (NASDAQ:EGRX) stands at $82.25 according to 4 Analysts. The higher price target estimate for the stock has been calculated at $98 while the lower price target estimate is at $71.

For the current week, the company shares have a recommendation consensus of Buy.

On the companys insider trading activities, The director officer (President and CEO), of Eagle Pharmaceuticals, Inc., Tarriff Scott had unloaded 30,765 shares at $40.63 per share in a transaction on April 1, 2016. The total value of transaction was $1,249,982. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.

Eagle Pharmaceuticals (NASDAQ:EGRX) stock ended Monday session in the red zone in a volatile trading. The stock closed down 2.15 points or 4.06% at $50.85 with 1,378,080 shares getting traded. Post opening the session at $52.77, the shares hit an intraday low of $50.0605 and an intraday high of $53.36 and the price was in this range throughout the day. The company has a market cap of $795 million and the number of outstanding shares have been calculated to be 15,636,387 shares. The 52-week high of Eagle Pharmaceuticals (NASDAQ:EGRX) is $104.17 and the 52-week low is $33.02.

Eagle Pharmaceuticals, Inc. (Eagle Pharmaceuticals) is a specialty pharmaceutical company. The Company focused on developing and commercializing injectable products. It develops products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially injectable products. Its two most advanced product candidates are EP-3101 (bendamustine RTD), an intravenous version of the chemotherapeutic agent that is marketed by Teva under the brand name Treanda, and Ryanodex (dantrolene for MH), and an intravenous version of an approved treatment for malignant hyperthermia. Its products include EP-3101, EP-3102, Ryanodex, EP-4104, EP-6101, EP-5101, EP-1101 and EP-2101. Teva markets its bendamustine product under the trade name Treanda.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.